OnabotulinumtoxinA Modulates Visual Cortical Excitability in Chronic Migraine: Effects of 12-Week Treatment.
Angelo TorrenteLaura PilatiSalvatore Di MarcoSimona MaccoraPaolo AlongeLavinia VassalloAntonino LupicaSerena CoppolaCecilia CamardaNadia BologniniFilippo BrighinaPublished in: Toxins (2022)
Chronic migraine is a burdensome disease presenting with episodic pain and several symptoms that may persist even among headache attacks. Multisensory integration is modified in migraine, as assessed by the level of the perception of sound-induced flash illusions, a simple paradigm reflecting changes in cortical excitability which reveals to be altered in migraineurs. OnabotulinumtoxinA is an effective preventive therapy for chronic migraineurs, reducing peripheral and central sensitization, and may influence cortical excitability. Patients affected by chronic migraine who started onabotulinumtoxinA preventive therapy were included. Clinical effects (headache diaries and migraine related questionnaires) were assessed at the beginning of the therapy and after 12 weeks. Contextually, patients underwent the evaluation of multisensory perception by means of the sound-induced flash illusions. OnabotulinumtoxinA showed effectiveness both in migraine prevention and in reducing headache burden. Even one session of therapy was able to restore, at least partially, multisensory processing, as shown by patients' susceptibility to the sound-induced flash illusion. OnabotulinumtoxinA could influence migraineurs cortical excitability concurrently to the beneficial effects in headache prevention.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- randomized controlled trial
- peritoneal dialysis
- drug induced
- transcranial direct current stimulation
- high glucose
- systematic review
- chronic pain
- oxidative stress
- depressive symptoms
- risk factors
- mesenchymal stem cells
- bone marrow
- working memory
- case report
- sleep quality